Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine

Successful treatment of infants with gastrointestinal involvement in Langerhans cell histiocytosis (LCH) has been poor, with no specific chemotherapeutic regimen of clear benefit. An 8-month-old male, diagnosed with LCH by skin and gastrointestinal biopsies, was treated with several cycles of 2-chlo...

Full description

Saved in:
Bibliographic Details
Published inJournal of pediatric hematology/oncology Vol. 25; no. 6; p. 503
Main Authors Choi, Sung W, Bangaru, Babu S, Wu, C Daniel, Finlay, Jonathan L
Format Journal Article
LanguageEnglish
Published United States 01.06.2003
Subjects
Biopsy
Cladribine - therapeutic use
Cytarabine - therapeutic use
Drug Therapy, Combination
Gastrointestinal Diseases - drug therapy
Gastrointestinal Diseases - etiology
Histiocytosis, Langerhans-Cell - complications
Histiocytosis, Langerhans-Cell - drug therapy
Humans
Immunosuppressive Agents - therapeutic use
Infant
Male
Online AccessGet more information

Cover

More Information
Summary:Successful treatment of infants with gastrointestinal involvement in Langerhans cell histiocytosis (LCH) has been poor, with no specific chemotherapeutic regimen of clear benefit. An 8-month-old male, diagnosed with LCH by skin and gastrointestinal biopsies, was treated with several cycles of 2-chlorodeoxyadenosine, vinblastine and prednisone with only partial response. Ultimately, two cycles of 2-chlorodeoxyadenosine concomitant with high-dose cytarabine led to a durable complete response. Twenty-seven months since the last course of chemotherapy, the patient continues to thrive free of disease. Treatment with 2-chlorodeoxyadenosine and cytarabine should be considered for further study in patients with poor-prognosis LCH.
ISSN:1077-4114
DOI:10.1097/00043426-200306000-00016